Objective To evaluate the effect of C-C chemokine receptor 5-D32 (CCR5-D32) heterozygosity of HIV-1-infected patients on the virological and immunological responses to highly-active antiretroviral therapy (HAART). Methods A literature search on the articles published before October 1, 2015 was conducted in the PubMed, Web of Science and China Biology Medicine databases. Results Eleven studies on virological response and only four studies on immunological response were eligible for inclusion. Populations with CCR5-D32 heterozygosity had stronger virological (■ = 1.24；95% CI = 1.15-1.35；P = 0.000) and immunological (■ = 1.17；95% CI = 1.04-1.31；P = 0.009) responses to HAART. There was a significant association between CCR5-D32 heterozygosity and stronger virological response in studies that involved at least one year of observation and a high threshold of detection for HIV RNA. Due to an insufficient number of eligible studies, further subgroup analyses of immunological responses could not be performed. Conclusions Stronger virological response has been found in the populations with CCR5-D32 heterozygosity. The association of CCR5-D32 heterozygosity with immunological response still needs further confirmation.